CUSIP: 36870A108
Q4 2017 13F Holders as of 31 Dec 2017
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
3,305,410
-
Share change
-
-108,358
-
Total reported value
-
$26,413,000
-
Price per share
-
$7.95
-
Number of holders
-
28
-
Value change
-
-$879,756
-
Number of buys
-
11
-
Number of sells
-
8
Quarterly Holders Quick Answers
What is CUSIP 36870A108?
CUSIP 36870A108 identifies GEMP - GEMPHIRE THERAPEUTICS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q1 2018
-
Previous quarter:
Q3 2017
Recent filing periods for CUSIP 36870A108:
Institutional Holders of GEMPHIRE THERAPEUTICS INC - COM (GEMP) as of Q4 2017
As of 31 Dec 2017,
GEMPHIRE THERAPEUTICS INC - COM (GEMP) was held by
28 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,305,410 shares.
The largest 10 holders included
Cormorant Asset Management, LLC, Exchange Capital Management, Inc., NORTHPOINTE CAPITAL LLC, BAMCO INC /NY/, ADAGE CAPITAL PARTNERS GP, L.L.C., Vanguard Group Inc, Cambridge Investment Research Advisors, Inc., COMERICA BANK, BRIDGEWAY CAPITAL MANAGEMENT INC, and RAYMOND JAMES & ASSOCIATES.
This page lists
28
institutional shareholders reporting positions in this security
for the Q4 2017 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.